Drug Trial Radar · NCT07931599
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,060
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Jul 24, 2028
Study completion Aug 28, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Conditions
- Diabetes Mellitus, Type 2
Interventions
ZenagamtideDrug
Zenagamtide will be administered subcutaneously once weekly.
SemaglutideDrug
Semaglutide will be administered subcutaneously once weekly.
Placebo zenagamtideDrug
Placebo volume-matched to zenagamtide will be administered subcutaneously once weekly.
Placebo semaglutideDrug
Placebo volume-matched to semaglutide will be administered subcutaneously once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 52
Locations
152 sites in 16 countries. Site status is shown where the registry gives one.
Scripps Whittier Diabetes Inst
La Jolla, California
First Valley Medical Group
Lancaster, California
Headlands Research CTR Lincoln
Lincoln, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
UC Anschutz Medical Campus
Aurora, Colorado
Northeast Research Institute
Fleming Island, Florida
Encore Medical Research LLC
Hollywood, Florida
Northeast Research Institute
Jacksonville, Florida
University of Florida, College of Medicine Jacksonville
Jacksonville, Florida
My Preferred Research
Miami, Florida
New Horizon Research Center
Miami, Florida
Adult Medicine of Lake County, Inc
Mt. Dora, Florida
True Blue Clinical Research
Tampa, Florida
Encore Medical Research of Weston
Weston, Florida
Hope Clin Res & Wellness
Conyers, Georgia
Cedar-Crosse Research Center
Chicago, Illinois
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Alliance for Multispec Res
Newton, Kansas
MedStar Health Research Institute
Olney, Maryland
Endo And Metab Cons
Rockville, Maryland
Elite Clinical Research Center
Flint, Michigan
Diabetes & Endo Specialists Inc
Chesterfield, Missouri
StudyMetrix Research LLC
City of Saint Peters, Missouri
Palm Research Center Inc-Vegas
Las Vegas, Nevada
Southern NH Diabetes and Endo_Nashua
Nashua, New Hampshire
AMC Community Endocrinology
Albany, New York
Southgate Medical Group, LLP
West Seneca, New York
Great Lakes Medical Research
Westfield, New York
PHC Accelacare
Statesville, North Carolina
Diab & Endo Assoc of Stark Co
Canton, Ohio
Tribe Clinical Research LLC
Greer, South Carolina
South Dakota Urban Indian Health
Sioux Falls, South Dakota
Holston Medical Group
Kingsport, Tennessee
Clinical Research Associates
Nashville, Tennessee
Victorium Clinical Research
Houston, Texas
Southwest Clinical Trials
Houston, Texas
Medical Colleagues-Texas LLP
Katy, Texas
Pinnacle Clinical Research
San Antonio, Texas
Northeast Clinical Research of San Antonio
San Antonio, Texas
Diabetes & Endo Treatment Spec
Sandy City, Utah
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.